Impact of Genotype, Serum Bile Acids, and Surgical Biliary Diversion on Native Liver Survival in FIC1 Deficiency
Yazar
Lipinski, Patryk
Azaz, Amer
Brecelj, Jernej
Dersofi, Antal
Calvo, Pier Luigi
Krebs-Schmitt, Dorothee
Hartleif, Steffen
van der Woerd, Wendy L.
Wang, Jian-She
Li, Li-ting
Durmaz, Ozlem
Kerkar, Nanda
Jorgensen, Marianne Horby
Fischer, Ryan
Jimenez-Rivera, Carolina
Alam, Seema
Cananzi, Mara
Laverdure, Noemie
Ferreira, Cristina Targa
Ordonez, Felipe
Wang, Heng
Sency, Valerie
Kim, Kyung Mo
Chen, Huey-Ling
Carvalho, Elisa
Fabre, Alexandre
Horslen, Simon
Kamath, Binita M.
Rogalidou, Maria
Karnsakul, Wikrom W.
Hansen, Bettina
Verkade, Henkjan J.
Thompson, Richard J.
Gonzales, Emmanuel
Jankowska, Irena
Shneider, Benjamin L.
Quintero Bernabeu, Jesus
Alonso, Estella M.
Sokol, Ronald J.
Suchy, Frederick J.
Loomes, Kathleen M.
McKiernan, Patrick J.
Rosenthal, Philip
Turmelle, Yumirle
Rao, Girish S.
Sokal, Etienne
Grammatikopoulos, Tassos
Kadaristiana, Agustina
Jacquemin, Emmanuel
Spraul, Anne
van Wessel, Daan B. E.
Czubkowski, Piotr
Rock, Nathalie
Shagrani, Mohammad
Broering, Dieter
Algoufi, Talal
Mazhar, Nejat
Nicastro, Emanuele
Kelly, Deirdre
Nebbia, Gabriella
Arnell, Henrik
Fischler, Bjorn
Hulscher, Jan B. F.
Serranti, Daniele
Arikan, Cigdem
Debray, Dominique
Lacaille, Florence
Goncalves, Cristina
Hierro, Loreto
Munoz Bartolo, Gema
Mozer-Glassberg, Yael
Üst veri
Tüm öğe kaydını gösterÖzet
Background and Aims Mutations in ATPase phospholipid transporting 8B1 (ATP8B1) can lead to familial intrahepatic cholestasis type 1 (FIC1) deficiency, or progressive familial intrahepatic cholestasis type 1. The rarity of FIC1 deficiency has largely prevented a detailed analysis of its natural history, effects of predicted protein truncating mutations (PPTMs), and possible associations of serum bile acid (sBA) concentrations and surgical biliary diversion (SBD) with long-term outcome. We aimed to provide insights by using the largest genetically defined cohort of patients with FIC1 deficiency to date. Approach and Results This multicenter, combined retrospective and prospective study included 130 patients with compound heterozygous or homozygous predicted pathogenic ATP8B1 variants. Patients were categorized according to the number of PPTMs (i.e., splice site, frameshift due to deletion or insertion, nonsense, duplication), FIC1-A (n = 67; no PPTMs), FIC1-B (n = 29; one PPTM), or FIC1-C (n = 34; two PPTMs). Survival analysis showed an overall native liver survival (NLS) of 44% at age 18 years. NLS was comparable among FIC1-A, FIC1-B, and FIC1-C (% NLS at age 10 years: 67%, 41%, and 59%, respectively; P = 0.12), despite FIC1-C undergoing SBD less often (% SBD at age 10 years: 65%, 57%, and 45%, respectively; P = 0.03). sBAs at presentation were negatively associated with NLS (NLS at age 10 years, sBAs P = 0.03). SBD decreased sBAs (230 [125-282] to 74 [11-177] mu mol/L; P = 0.005). SBD (HR 0.55, 95% CI 0.28-1.03, P = 0.06) and post-SBD sBA concentrations < 65 mu mol/L (P = 0.05) tended to be associated with improved NLS. Conclusions Less than half of patients with FIC1 deficiency reach adulthood with native liver. The number of PPTMs did not associate with the natural history or prognosis of FIC1 deficiency. sBA concentrations at initial presentation and after SBD provide limited prognostic information on long-term NLS.
Koleksiyonlar
- Makale [92796]